[en] AIM: To study the signature of 87 urinary miRNAs in Duchenne muscular dystrophy (DMD) patients, select the most dysregulated and determine statistically significant differences in their expression between controls, ambulant (A) and nonambulant (NA) DMD patients, and patients on different corticosteroid regimens. Patients/materials & methods: Urine was collected from control (n = 20), A (n = 31) and NA (n = 23) DMD patients. miRNA expression was measured by reverse transcription-quantitative PCR. RESULTS: miR-29c-3p was significantly downregulated in A DMD patients while miR-23b-3p and miR-21-5p were significantly downregulated in NA DMD patients compared with age-matched controls. CONCLUSION: miR-29c-3p, miR-23b-3p and miR-21-5p are promising novel noninvasive biomarkers for DMD, and miR-29c-3p levels are differentially affected by different steroid regimens, supporting the antifibrotic effect of steroid therapy.
Disciplines :
Neurology Pediatrics
Author, co-author :
Catapano, Francesco
Domingos, Joana
Perry, Mark
Ricotti, Valeria
Phillips, Lauren
Servais, Laurent ; Université de Liège - ULiège > Département des sciences cliniques > Neuropédiatrie
Mendell JR, Shilling C, Leslie ND et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann. Neurol. 71(3), 304-313 (2012).
Ferlini A, Neri M, Gualandi F. The medical genetics of dystrophinopathies: molecular genetic diagnosis and its impact on clinical practice. Neuromuscul. Disord. 23(1), 4-14 (2013).
Den Dunnen JT, Grootscholten PM, Bakker E et al. Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications. Am. J. Hum. Genet. 45(6), 835-847 (1989).
Gumerson JD, Michele DE. The dystrophin-glycoprotein complex in the prevention of muscle damage. J. Biomed. Biotechnol. 2011, 210797 (2011).
Ricotti V, Ridout DA, Scott E et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J. Neurol. Neurosurg. Psychiatry 84(6), 698-705 (2013).
Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst. Rev. 5, CD003725 (2016).
Wehling-Henricks M, Lee JJ, Tidball JG. Prednisolone decreases cellular adhesion molecules required for inflammatory cell infiltration in dystrophin-deficient skeletal muscle. Neuromuscul. Disord. 14(8-9), 483-490 (2004).
Wong BL, Christopher C. Corticosteroids in Duchenne muscular dystrophy: a reappraisal. J. Child Neurol. 17(3), 183-190 (2002).
Morrison-Nozik A, Anand P, Zhu H et al. Glucocorticoids enhance muscle endurance and ameliorate Duchenne muscular dystrophy through a defined metabolic program. Proc. Natl Acad. Sci. USA 112(49), e6780-e6789 (2015).
Gonzalez-Bermejo J, Lofaso F, Falaize L et al. Resting energy expenditure in Duchenne patients using home mechanical ventilation. Eur. Respir. J. 25(4), 682-687 (2005).
Bettica P, Petrini S, D'Oria V et al. Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscul. Disord. 26(10), 643-649 (2016).
Bushby K, Finkel R, Wong B et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 50(4), 477-487 (2014).
Lim KR, Maruyama R, Yokota T. Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des. Devel. Ther. 11, 533-545 (2017).
Guiraud S, Davies KE. Pharmacological advances for treatment in Duchenne muscular dystrophy. Curr. Opin. Pharmacol. 34, 36-48 (2017).
Ventura-Clapier R, Kuznetsov A, Veksler V, Boehm E, Anflous K. Functional coupling of creatine kinases in muscles: species and tissue specificity. Mol. Cell Biochem. 184(1-2), 231-247 (1998).
Nicholson GA, Morgan GJ, Meerkin M, Strauss ER, McLeod JG. The effect of aerobic exercise on serum creatine kinase activities. Muscle Nerve 9(9), 820-824 (1986).
Cherian AG, Hill JG. Age dependence of serum enzymatic activities (alkaline phosphatase, aspartate aminotransferase, and creatine kinase) in healthy children and adolescents. Am. J. Clin. Pathol. 70(5), 783-789 (1978).
Nadarajah VD, Van Putten M, Chaouch A et al. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). Neuromuscul. Disord. 21(8), 569-578 (2011).
Lourbakos A, Yau N, De Bruijn P et al. Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne. Sci. Rep. 7(1), 17888 (2017).
Rouillon J, Poupiot J, Zocevic A et al. Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies. Hum. Mol. Genet. 24(17), 4916-4932 (2015).
Rouillon J, Zocevic A, Leger T et al. Proteomics profiling of urine reveals specific titin fragments as biomarkers of Duchenne muscular dystrophy. Neuromuscul. Disord. 24(7), 563-573 (2014).
Ha M, Kim VN. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 15(8), 509-524 (2014).
O'Rourke JR, Georges SA, Seay HR et al. Essential role for Dicer during skeletal muscle development. Dev. Biol. 311(2), 359-368 (2007).
Dey BK, Gagan J, Dutta A. miR-206 and -486 induce myoblast differentiation by downregulating Pax7. Mol. Cell Biol. 31(1), 203-214 (2011).
Zhang Y, He W, Gao YF, Fan ZM, Gao CL, Xia ZK. MicroRNA106b regulates skeletal muscle insulin sensitivity and glucose homeostasis by targeting mitofusion2. Mol. Med. Rep. 16(5), 6858-6863 (2017).
Zaharieva IT, Calissano M, Scoto M et al. Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular Dystrophy. PLoS ONE 8(11), e80263 (2013).
Catapano F, Zaharieva I, Scoto M et al. Altered levels of MicroRNA-9, -206, and -132 in spinal muscular atrophy and their response to antisense oligonucleotide therapy. Mol. Ther. Nucleic Acids 5(7), e331 (2016).
Perry MM, Muntoni F. Noncoding RNAs and Duchenne muscular dystrophy. Epigenomics 8(11), 1527-1537 (2016).
Ichii O, Ohta H, Horino T et al. Urinary exosome-derived microRNAs reflecting the changes of renal function and histopathology in dogs. Sci. Rep. 7, 40340 (2017).
Romancino DP, Paterniti G, Campos Y et al. Identification and characterization of the nano-sized vesicles released by muscle cells. FEBS Lett. 587(9), 1379-1384 (2013).
Zhou H, Pisitkun T, Aponte A et al. Exosomal Fetuin-A identified by proteomics: a novel urinary biomarker for detecting acute kidney injury. Kidney Int. 70(10), 1847-1857 (2006).
Nilsson J, Skog J, Nordstrand A et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br. J. Cancer 100(10), 1603-1607 (2009).
Erbes T, Hirschfeld M, Rucker G et al. Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker. BMC Cancer 15, 193 (2015).
Fraser KB, Rawlins AB, Clark RG et al. Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease. Mov. Disord. 31(10), 1543-1550 (2016).
Wang L, Zhou L, Jiang P et al. Loss of miR-29 in myoblasts contributes to dystrophic muscle pathogenesis. Mol. Ther. 20(6), 1222-1233 (2012).
Zanotti S, Gibertini S, Curcio M et al. Opposing roles of miR-21 and miR-29 in the progression of fibrosis in Duchenne muscular dystrophy. Biochim. Biophys. Acta 1852(7), 1451-1464 (2015).
Koning M, Werker PM, Van Luyn MJ, Krenning G, Harmsen MC. A global downregulation of microRNAs occurs in human quiescent satellite cells during myogenesis. Differentiation 84(4), 314-321 (2012).
Zhou L, Wang L, Lu L, Jiang P, Sun H, Wang H. A novel target of microRNA-29, Ring1 and YY1-binding protein (Rybp), negatively regulates skeletal myogenesis. J. Biol. Chem. 287(30), 25255-25265 (2012).
Dmitriev P, Stankevicins L, Ansseau E et al. Defective regulation of microRNA target genes in myoblasts from facioscapulohumeral dystrophy patients. J. Biol. Chem. 288(49), 34989-35002 (2013).
Vignier N, Amor F, Fogel P et al. Distinctive serum miRNA profile in mouse models of striated muscular pathologies. PLoS ONE 8(2), e55281 (2013).
Babicki S, Arndt D, Marcu A et al. Heatmapper: web-enabled heat mapping for all. Nucleic Acids Res. 44(W1), W147-W153 (2016).
D'haene B, Mestdagh P, Hellemans J, Vandesompele J. miRNA expression profiling: from reference genes to global mean normalization. Methods Mol. Biol. 822, 261-272 (2012).
Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 64(15), 5245-5250 (2004).
Vlachos IS, Kostoulas N, Vergoulis T et al. DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res. 40, W498-W504 (2012).
Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 45(D1), D353-D361 (2017).
Alexander MS, Casar JC, Motohashi N et al. MicroRNA-486-dependent modulation of DOCK3/PTEN/AKT signaling pathways improves muscular dystrophy-associated symptoms. J. Clin. Invest. 124(6), 2651-2667 (2014).
Alexander MS, Kawahara G, Motohashi N et al. MicroRNA-199a is induced in dystrophic muscle and affects WNT signaling, cell proliferation, and myogenic differentiation. Cell Death Differ. 20(9), 1194-1208 (2013).
Jeanson-Leh L, Lameth J, Krimi S et al. Serum profiling identifies novel muscle miRNA and cardiomyopathy-related miRNA biomarkers in Golden Retriever muscular dystrophy dogs and Duchenne muscular dystrophy patients. Am. J. Pathol. 184(11), 2885-2898 (2014).
Cacchiarelli D, Legnini I, Martone J et al. miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Mol. Med. 3(5), 258-265 (2011).
Roberts TC, Blomberg KE, Mcclorey G et al. Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy. Mol. Ther. Nucleic Acids 1, e39 (2012).
Hu J, Kong M, Ye Y, Hong S, Cheng L, Jiang L. Serum miR-206 and other muscle-specific microRNAs as non-invasive biomarkers for Duchenne muscular dystrophy. J. Neurochem. 129(5), 877-883 (2014).
Kriegel AJ, Liu Y, Fang Y, Ding X, Liang M. The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol. Genomics 44(4), 237-244 (2012).
He Y, Huang C, Lin X, Li J. MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases. Biochimie 95(7), 1355-1359 (2013).
Kharraz Y, Guerra J, Pessina P, Serrano AL, Munoz-Canoves P. Understanding the process of fibrosis in Duchenne muscular dystrophy. Biomed. Res. Int. 2014, 965631 (2014).
Serrano AL, Munoz-Canoves P. Regulation and dysregulation of fibrosis in skeletal muscle. Exp. Cell Res. 316(18), 3050-3058 (2010).
Horiguchi M, Ota M, Rifkin DB. Matrix control of transforming growth factor-beta function. J. Biochem. 152(4), 321-329 (2012).
Zhou L, Porter JD, Cheng G et al. Temporal and spatial mRNA expression patterns of TGF-beta1, 2, 3 and TbetaRI, II, III in skeletal muscles of mdx mice. Neuromuscul. Disord. 16(1), 32-38 (2006).
Gosselin LE, Williams JE, Deering M, Brazeau D, Koury S, Martinez DA. Localization and early time course of TGF-beta 1 mRNA expression in dystrophic muscle. Muscle Nerve 30(5), 645-653 (2004).
Bernasconi P, Torchiana E, Confalonieri P et al. Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. J. Clin. Invest. 96(2), 1137-1144 (1995).
Cacchiarelli D, Martone J, Girardi E et al. MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway. Cell Metab. 12(4), 341-351 (2010).
Cushing L, Kuang PP, Qian J et al. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 45(2), 287-294 (2011).
Qin W, Chung AC, Huang XR et al. TGF-beta/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J. Am. Soc. Nephrol. 22(8), 1462-1474 (2011).
Klingler W, Jurkat-Rott K, Lehmann-Horn F, Schleip R. The role of fibrosis in Duchenne muscular dystrophy. Acta Myol. 31(3), 184-195 (2012).
Marques MJ, Oggiam DS, Barbin IC, Ferretti R, Santo Neto H. Long-term therapy with deflazacort decreases myocardial fibrosis in mdx mice. Muscle Nerve 40(3), 466-468 (2009).
Hartel JV, Granchelli JA, Hudecki MS, Pollina CM, Gosselin LE. Impact of prednisone on TGF-beta1 and collagen in diaphragm muscle from mdx mice. Muscle Nerve 24(3), 428-432 (2001).
Rogler CE, Levoci L, Ader T et al. MicroRNA-23b cluster microRNAs regulate transforming growth factor-beta/bone morphogenetic protein signaling and liver stem cell differentiation by targeting Smads. Hepatology 50(2), 575-584 (2009).
Chen M, Huang L, Zhang W et al. MiR-23b controls TGF-beta1 induced airway smooth muscle cell proliferation via TGFbetaR2/p-Smad3 signals. Mol. Immunol. 70, 84-93 (2016).
Wilkes MC, Leof EB. Transforming growth factor beta activation of c-Abl is independent of receptor internalization and regulated by phosphatidylinositol 3-kinase and PAK2 in mesenchymal cultures. J. Biol. Chem. 281(38), 27846-27854 (2006).
Pellegrino L, Stebbing J, Braga VM et al. miR-23b regulates cytoskeletal remodeling, motility and metastasis by directly targeting multiple transcripts. Nucleic Acids Res. 41(10), 5400-5412 (2013).
Micallef L, Vedrenne N, Billet F, Coulomb B, Darby IA, Desmouliere A. The myofibroblast, multiple origins for major roles in normal and pathological tissue repair. Fibrogenesis Tissue Repair 5(Suppl. 1), S5 (2012).
Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc. Natl Acad. Sci. USA 101(36), 13368-13373 (2004).
Gasparri ML, Casorelli A, Bardhi E et al. Beyond circulating microRNA biomarkers: urinary microRNAs in ovarian and breast cancer. Tumour Biol. 39(5), 1010428317695525 (2017).
Stuopelyte K, Daniunaite K, Bakavicius A, Lazutka JR, Jankevicius F, Jarmalaite S. The utility of urine-circulating miRNAs for detection of prostate cancer. Br. J. Cancer 115(6), 707-715 (2016).
Abdalla MA, Haj-Ahmad Y. Promising candidate urinary MicroRNA biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus Egyptian patients. J. Cancer 3, 19-31 (2012).
Ricotti V, Ridout DA, Pane M et al. The NorthStar ambulatory assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. J. Neurol. Neurosurg. Psychiatry 87(2), 149-155 (2016).
McDonald CM, Henricson EK, Abresch RT et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet 391(10119), 451-461 (2017).